The PI 3-kinases (PI3K) are essential mediators of chemokine receptor signaling necessary for migration of chronic lymphocytic leukemia (CLL) cells and their interaction with tissue-resident stromal cells. While the PI3Kδ-specific inhibitor idelalisib shows efficacy in treatment of CLL and other B cell malignancies, the function of PI3Kγ has not been extensively studied in B cells. Here, we assess whether PI3Kγ has non-redundant functions in CLL migration and adhesion to stromal cells. We observed that pharmaceutical PI3Kγ inhibition with CZC24832 significantly impaired CLL cell migration, while dual PI3Kδ/γ inhibitor duvelisib had a greater impact than single isoform-selective inhibitors. Knockdown of PI3Kγ reduced migration of CLL cells and cell lines. Expression of the PI3Kγ subunits increased in CLL cells in response to CD40L/IL-4, whereas BCR cross-linking had no effect. Overexpression of PI3Kγ subunits enhanced cell migration in response to SDF1α/ CXCL12, with the strongest effect observed within ZAP70 + CLL samples. Microscopic tracking of cell migration within chemokine gradients revealed that PI3Kγ functions in gradient sensing and impacts cell morphology and F-actin polarization. PI3Kγ inhibition also reduced CLL adhesion to stromal cells to a similar extent as idelalisib. These findings provide the first evidence that PI3Kγ has unique functions in malignant B cells.
Introduction
Chronic lymphocytic leukemia (CLL) is a prevalent hematologic malignancy affecting adults in the West. CLL cells rely on chronic activation triggered via the B cell receptor (BCR) to potentiate their survival [1] . Within lymphoid tissues, CLL cells interact with and shape a microenvironment favorable to their survival and proliferation [2] . They migrate to favorable niches in response to chemotactic factors, such as the chemokine stromal-derived factor 1 (SDF1α). They interact with resident stromal cells that provide them with survival and proliferative stimuli through cell-cell contact and soluble factors [3] [4] [5] . The protective microenvironment shields CLL cells from the effects of therapeutics, conferring a resistant phenotype.
CLL varies from indolent to progressive forms according to the expression of several biomarkers, immunoglobulin variable heavy chain (IgVH) mutation, and chromosomal abnormalities [6, 7] . One such biomarker is the expression of zeta-chain T cell receptor-associated protein kinase 70 kDa (ZAP70) [8, 9] . We and others have shown that ZAP70 expression can alter CLL adhesion and migration [10] [11] [12] ; however, the mechanisms for this remain unclear.
The phosphoinositide 3-kinase (PI3K) signaling pathway has been implicated in numerous malignancies [13] [14] [15] [16] [17] . PI3K enzymes phosphorylate the 3′ hydroxyl group of the inositol ring of phosphoinositide lipids. PI3Kδ has established functions in normal and malignant B cell signaling, and the p110δ-specific inhibitor idelalisib has been effective in CLL treatment [18, 19] . Inhibition of PI3Kδ affects multiple aspects of CLL biology, including cell adhesion and migration in response to chemokines [20, 21] .
PI3Kγ consists of a catalytic subunit (p110γ) and one of two regulatory subunits (p84 or p101), which bind to p110γ and have different effects on p110γ activity in terms of cellular migration [22, 23] . PI3Kγ is recruited to activated chemokine receptors via p101-dependent binding to Gβ/γ subunits [24] [25] [26] , whereas the mechanism of PI3Kδ activation by chemokines is unclear. PI3Kγ has wellestablished functions in T lymphocyte and neutrophil chemokine receptor signaling, but has not been extensively studied in B lymphocytes [27, 28] . In fact, the limited data available on B cell function in PI3Kγ-deficient mice indicate that this enzyme is not essential for B cell activation or migration [29, 30] . Despite this, PI3Kγ inhibitors are now in clinical development for B cell malignancies [31] .
In this study, we present our novel findings that PI3Kδ and PI3Kγ have unique, non-redundant functions in CLL cell migration and adhesion to stromal cells. These findings indicate that targeting PI3Kγ alone or in combination with PI3Kδ may have a unique impact on CLL biology with potential therapeutic benefit.
Materials and methods

CLL cells and cell lines
CLL cells were isolated from peripheral blood samples using RosetteSep Human B Cell Enrichment Cocktail (Stemcell Technologies) at CancerCare Manitoba with the approval of the Research Ethics Board at the University of Manitoba. ZAP70 and IgVH mutation status were determined as previously described [32] . Patient characteristics are described in Table S1 . CLL-derived JVM3 and Burkitt lymphoma Ramos cells were obtained from DSMZ, Germany. HS-5 human bone marrow-derived stromal cells were obtained from ATCC. All cells were grown in RPMI1640 media supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (GIBCO).
Chemicals and reagents
PI3K inhibitors CZC24832, GS-1101/idelalisib, IPI-145/ duvelisib, and GDC-0980/apitolisib (Selleck Chemicals) were reconstituted in DMSO (Sigma) and used at final concentrations of 2 μM (CZC24832) and 1 μM (idelalisib, duvelisib, GDC-0980). CZC24832 has greater than 10-fold selectivity over PI3Kβ and greater than 100-fold selectivity over PI3Kα and PI3Kδ [33] . α-IgM F(ab′) 2 (Southern Biotech) was used at 10 μg/ml and CD40 ligand and interleukin 4 (R&D systems) were used at 50 ng/ml each. Anti-p110γ antibody, anti-Akt antibody, anti-pAkt Ser473 antibody, anti-GAPDH antibody (Cell Signaling), anti-p101 antibody (R&D systems), and Mini-PROTEAN TGX precast gels (Bio-Rad) were used for Western blot analysis. SDF1α (Peprotech) was used at 100 ng/ml. Alexa Fluor ® 488 Phalloidin (Life Technologies) was used at 33 nM for F-actin staining. Superscript VILO cDNA mix (Invitrogen) was used for RT-qPCR. DAPI, trypsin-EDTA (Sigma), and anti CD19-FITC antibody (BD Biosciences) were used for the cell adhesion assay.
Western blotting
The experiments were performed as previously described [34] . Membranes were incubated overnight at 4°C with anti-p110γ and anti-p101 antibodies (1:1000 dilution). GAPDH served as a loading control (1:10,000 dilution). HRP-conjugated anti-rabbit (Cell Signaling) and anti-mouse (Jackson Immunoresearch) secondary antibodies (1:5000 dilution) were used for chemiluminescent detection.
Real-time quantitative PCR
The experiments were performed as previously described [35] . Briefly, 5 million CLL cells per treatment group were stimulated for 24 h with α-IgM or CD40L/IL-4, collected in TRIzol, and total RNA was isolated and purified using the Purelink RNA kit (Thermo Fisher). qPCR was performed using a LightCycler 96 PCR instrument (Roche Diagnostics) and Power SYBR green (Applied Biosystems). All reactions were run in duplicates (primer sequences available in Fig. S1A ).
Plasmid constructs
Expression vectors for p110γ-GFP or p101-GFP used the pLenti-GIII-CMV-GFP-2A-Puro backbone (Applied Biological Materials). The expression vector for dCas9-GFP is pLV-hUbc-dCas9-T2A-GFP (Addgene #53191). Guide RNA expression cassettes targeting the p110γ gene were designed based on a CRISPRi optimized gRNA sequence library [36] and synthesized by Integrated DNA Technologies (sequences in Fig. S1B ). gRNA cassettes were cloned into the XbaI/XhoI sites of vector pU6-sgRNA EF1Alphapuro-T2A-BFP (Addgene #60955) for use in CRISPRi ( Fig. S1B ). For CRISPRi experiments, the two p110γ gRNA plasmid vectors were mixed with dCas9-GFP plasmid at a 3:1 ratio (gRNA:dCas9) for transfection.
Cell transfection
For cell lines, 5 × 10 5 cells were transfected with each plasmid (1 μg) using the Neon Transfection system (Invitrogen), with the following conditions: JVM3 1200 V, 20 ms, 2 pulses; Ramos 1600 V, 20 ms, 1 pulse. For primary CLL cells, 1 × 10 6 cells were transfected with each plasmid (2.5 μg) using 2250 V, 20 ms, 1 pulse. Transfection efficiency was 20-30% for cell lines and 8-12% for primary CLL as assessed by GFP expression.
Transwell migration and adhesion assays
The experiments were performed as previously described [32, 37] . Migration assays used Corning transwell plates containing 5 × 10 5 cells and 8 μm insert (cell lines) and 1 × 10 6 cells and 5 μm insert (CLL), and SDF1α (3 h). Adhesion assays used 5 × 10 4 HS-5 cells/well and 5 × 10 6 primary CLL cells/well (24 h). Migrated/non-migrated fractions and adhered/non-adhered fractions were collected and counted by flow cytometry gating on live B cells.
Microscopy-based chemokinesis and chemotaxis assays
For chemokinesis assays, μ-Slide 8-well chamber slides (Ibidi) were coated with 1 µg/ml VCAM-1 at 4°C overnight and washed with warm RPMI1640. 1 × 10 5 Ramos cells were added to allow adhesion (0.5 h), then incubated with the inhibitors (0.5 h) in serum-free medium. After adding SDF1α, migration was assessed by time-lapse imaging. For chemotaxis assays, μ-Slide Chemotaxis 3D chambers were pre-warmed to 37°C prior to addition of cell/collagen mixtures. Collagen gel mixtures (1.7 mg/ml) were made using PureCol Bovine Collagen (Advanced Biomatrix) and kept on ice [38] . JVM3 cells (3 × 10 6 /ml) and inhibitors were added, and the mixture was loaded into the chambers. Cell migration was recorded by Zeiss AxioObserver confocal microscope equipped with environmental control (37°C, 5% CO 2 ). 
Cell tracking and data analysis
Intracellular staining, morphological scoring, and confocal microscopy
Ramos cells were added to VCAM-1-coated chamber slides to allow adhesion (0.5 h) then incubated with the inhibitors (0.5 h) in serum-free medium. Cells were then stimulated (SDF1α) for the indicated time, fixed (2% PFA), permeabilized (0.5% saponin), washed and stained for F-actin using Alexa Fluor ® 488 phalloidin (33 nM). Images were taken by Zeiss AxioObserver confocal microscope under 63× magnification.
Statistical analysis
Unless indicated otherwise, Student's t-test was used to calculate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001). Error bars represent SEM.
Results
Inhibition of PI3Kγ impairs cell migration to a similar extent as PI3Kδ inhibition
Inhibition of PI3Kδ impairs malignant B cell adhesion and migration [32, 39] ; however, the role of PI3Kγ in this context is unknown. To assess the roles of each PI3K isoform in the regulation of CLL cell migration, we have used isoform-specific inhibitors CZC24832 (PI3Kγ-specific), GS-1101/idelalisib (PI3Kδ-specific), and dual PI3Kδ/PI3Kγ inhibitor IPI-145/duvelisib. Pan-PI3K inhibitor GDC-0980/ apitolisib was used as a positive control. JVM3 cells, maintained in medium or stimulated for 24 h with CD40L/ IL-4, were pre-incubated (1 h) with CZC24832, idelalisib, duvelisib, or GDC-0980. Migration capacity was assessed using a transwell chamber containing SDF1α in the bottom chamber and the inhibitors in both top and bottom chambers to ensure continued inhibition during the assay. We found that PI3Kγ inhibition significantly reduced the migration of stimulated JVM3 cells to a similar extent as PI3Kδ inhibition ( Fig. 1a ). Dual PI3Kδ/PI3Kγ inhibition further decreased JVM3 cell migration to a level comparable to pan-PI3K inhibition ( Fig. 1A) . Western blot analysis revealed that CZC24832 reduced SDF1α-induced phosphorylation of Akt in a dose-dependent manner ( Fig. 1B) .
We then assessed the sensitivity of CLL cell migration to these inhibitors under the same conditions and observed that PI3Kγ inhibition alone is sufficient to significantly decrease CLL cell migration, with or without CD40L/IL-4 prestimulation ( Fig. 2A−C) . PI3Kγ or PI3Kδ inhibitors reduced CLL migration to a similar extent, whereas dual inhibition with duvelisib had a significantly greater impact on migration than PI3Kγ inhibition alone ( Fig. 2A−B) . Moreover, the combination of CZC24832 and idelalisib had a significantly greater effect on CLL migration than either inhibitor alone ( Fig. 2C ). Grouping CLL patients based on major prognostic markers showed that PI3Kγ inhibition sensitivity was similar in progressive and indolent disease groups defined by ZAP70 or IgVH mutation status ( Fig. S2 ). Consistent with these functional data, PI3Kγ inhibition reduced phosphorylation of Akt and its downstream targets GSK3β and S6 kinase in CLL cells and greater inhibition was observed with dual PI3Kδ/PI3Kγ inhibition ( Fig. S3A ). Inhibitor treatments did not affect relative expression of different PI3K isoforms ( Fig. S3B ) or cell viability ( Fig. S4 ). Migration of normal human B cells was also significantly impaired by idelalisib, duvelisib, and GDC-0980, whereas PI3Kγ inhibitor had a relatively small effect that did not reach statistical significance (Fig. S5 ). Together, these results provide the first demonstration that PI3Kγ has a nonredundant role in CLL cell migration, and suggest that combined PI3Kγ and PI3Kδ targeting may in some contexts have a greater impact than targeting either isoform alone.
Knockdown of p110γ significantly reduced CLL cell migration
We employed CRISPRi technology to provide an independent means of assessing the importance of PI3Kγ in CLL cell migration. Two guide RNAs were designed targeting different sites of the p110γ gene, and co-expressed with dCas9-GFP in malignant B cell lines Ramos and JVM3. This method was sufficient to significantly and specifically reduce p110γ expression as determined by qPCR analysis of p110 subunit expression ( Fig. 3A and . b Effect of PI3Kγ inhibitor on Akt phosphorylation. JVM3 cells were pre-incubated with the indicated concentrations of CZC4832 (in μM) and then stimulated with SDF1α for 10 min. Akt Ser473 phosphorylation and total Akt levels were assessed by Western blot Fig. S6A ). Following a 48 h recovery period, transfected cells were assessed for migration using a transwell assay. We observed that p110γ downregulation significantly reduced cell migration compared to control cells ( Fig. 3B ). Moreover, knockdown of p110γ in primary CLL cells significantly reduced their migration independently of IgVH mutation status ( Fig. 3C ) and ZAP70 expression ( Fig. S6B ), without compromising cell viability ( Fig. S4B ). These results are consistent with those seen with PI3Kγ inhibition, and confirm that PI3Kγ has an independent and essential function in malignant B cell migration.
Expression of PI3Kγ in CLL cells is enhanced in response to CD40L/IL-4 stimulation independently of ZAP70 status or IgVH mutation
We examined the expression of PI3Kγ subunits in CLL prognostic groups and determined whether PI3Kγ expression is influenced by BCR cross-linking or stimulation with T cell-derived factors. Purified CLL cells were stimulated (24 h) with α-IgM or CD40L/IL-4 and mRNA abundance of p110γ and p101 were determined. We observed that the expression of p110γ mRNA was significantly upregulated after CD40L/IL-4 stimulation, but not after α-IgM stimulation, regardless of ZAP70 or IgVH mutation status ( Fig. 4A and Fig. S7A ). Both α-IgM and CD40L/IL-4 stimulation were able to activate the PI3K kinase signaling pathway in CLL ( Fig. S8 ). Expression of p101 was highly heterogeneous, but the majority of CLL patients showed increased p101 expression after CD40L/IL-4 stimulation ( Fig. 4B and Fig. S7B ). Interestingly, a few patients who expressed p101 at high levels without stimulation showed the reverse trend ( Fig. S7B ), suggesting that distinct mechanisms may maintain high p101 expression in these patients. Examination of p110γ and p101 protein expression also indicated heterogeneity and a trend of increased expression after CD40L/IL-4 stimulation (Fig. 4C ). Analysis of microarray data generated from leukemic B cells isolated from CLL patient peripheral blood or lymph nodes Effect of PI3Kγ inhibitor on CLL cell migration. CLL cells were cultured in medium or stimulated with CD40L+IL-4 for 24 h and subjected to a transwell migration assay. Graphs represent migration of cells from individual CLL patient samples with or without addition of PI3Kγ inhibitor CZC24832, connected by lines. b Inhibition of PI3Kγ or PI3Kδ decreases the migration of CLL cells to a similar extent, while dual PI3Kδ/γ inhibition using duvelisib has significantly greater effect than PI3Kγ inhibitor alone. c Combination of PI3Kγ inhibitor and PI3Kδ inhibitor decreases the migration of CLL cells to a greater extent than either inhibitor alone. Lines connect individual patient sample migration responses in the presence of the indicated inhibitors. Note all inhibitor-treated groups were significantly different than the control untreated group, whereas the CZC24832+idelalisib combination was not significantly different than duvelisib.
(GEO data set GDS4176; [40] ) revealed that both p110γ and p101 are more highly expressed in lymph node than peripheral blood (Fig. S9 ). Together, these results indicate that CLL cells express PI3Kγ and its expression can be modulated by factors present in the lymphoid tissue microenvironment.
Overexpression of PI3Kγ enhances chemokineinduced cell migration
To determine whether increased PI3Kγ expression can impact the migration of CLL cells, p110γ or p101 subunits were each overexpressed in JVM3 cells. After transfection with either p110γ-GFP or p101-GFP expression plasmids, overexpression was confirmed by qPCR ( Fig. 5A ). Migration of the transfected cells was measured using the transwell assay. We found that chemokine-induced migration of JVM3 cells is significantly increased by overexpression of either p110γ or p101 (Fig. 5B) . We further determined the impact of PI3Kγ subunits on migration of CLL cells. While overexpression of p101 did not increase CLL migration, overexpression of p110γ resulted in significant but variable increases in migration ( Fig. 5C ). Co-expression of both p110γ and p101 significantly increased migration in the majority of CLL patient samples, and had a significantly greater impact than expression of p110γ alone (Fig. 5C ). Together these data support the importance of PI3Kγ in CLL cell migration and suggest that its expression level is an important factor determining cellular migration capacity.
Impact of PI3Kγ or PI3Kδ inhibition on cell migration behavior within chemokine gradients
Unlike PI3Kδ, PI3Kγ is known to directly associate with G-protein-coupled receptors via binding to activated Gβ/γ subunits [25, 41] and can mediate directional migration within chemokine gradients [29, 30, 42] . To determine whether PI3Kγ and PI3Kδ may affect distinct migration behaviors, cells were observed by video microscopy and migration analyzed by cell tracking software. We first measured migration of Ramos cells plated on a VCAM-1coated glass surface and stimulated with SDF1α and found that inhibition of either PI3Kγ or PI3Kδ impair migration velocity ( Fig. S10A ) and mean squared displacement [33] , a measure of directional migration persistence (Fig. S10B ). We then assessed migration within a microfluidic device containing an SDF1α gradient within a collagen gel to allow determination of the chemotactic index, a measure of directional migration reflecting the ability of cells to detect the chemokine gradient [43] . Analyses of JVM3 cell migration tracks within this gradient system (Fig. 6A ) revealed that either PI3Kδ or PI3Kγ inhibition were sufficient to reduce the chemotactic index ( Fig. 6B ) and migration velocity (Fig. 6C ) under these conditions, with PI3Kγ inhibition showing the strongest effect. 
PI3Kγ or PI3Kδ inhibition differentially affect cytoskeletal remodeling and cell morphology
We noted that PI3Kγ inhibitor-treated cells frequently show abnormal morphologies after SDF1α stimulation, including dynamic multiple protrusions that fail to develop into fully polarized leading edges (Fig. 7A) . We microscopically scored cells exhibiting round, elongated, polarized, or multiprotrusion morphologies by fixing cells after 1 min of SDF1α stimulation and staining the F-actin cytoskeleton (Fig. 7B) . It was found that either PI3Kδ or PI3Kγ inhibition was sufficient to reduce the proportion of fully polarized cells and increase the proportion of elongated or multi-protrusion morphologies; however, PI3Kγ inhibition decreased polarization and increased multi-protrusion morphologies to a greater extent than PI3Kδ inhibition (Fig. 7C ). Together these results indicate a unique and non-redundant role for PI3Kγ in mediating chemokine-induced alterations in the cytoskeleton and chemokine gradient sensing.
Inhibition of either PI3Kγ or PI3Kδ significantly decreases the adhesion of CLL cells to bone marrowderived stromal cells
Adhesion of CLL cells to stromal cells is driven by chemokines such as SDF1α and promotes their retention and interaction with other cell types present in the lymphoid tissue microenvironment [2, 32] . To determine the roles of PI3Kγ and PI3Kδ in the interaction of CLL cells and stromal cells, we co-cultured CLL cells with human stromal cell line HS-5 with or without specific PI3K inhibitors. After 24 h, the non-adhered CLL cells were collected and then adhered cells along with the stromal cells were removed using trypsin. CD19-expressing cells in the adhered and non-adhered fractions were counted by flow cytometry and the adhesion index was calculated accordingly. We found that PI3Kγ inhibition significantly reduced binding to stromal cells, and dual inhibition of PI3Kγ and PI3Kδ had a stronger effect than PI3Kγ inhibition alone (Fig. 8A) . While basal adhesion to stromal cells was higher in ZAP70 + CLL cells as expected, the inhibition of either PI3Kγ or PI3Kδ significantly decreased CLL cell adhesion in both ZAP70+ and ZAP70− groups (Fig. 8B) . In both patient groups, duvelisib had a stronger effect than either single isoform inhibitor ( Fig. 8B−C) . These differences in response to the inhibitors were not due to differences in cell viability as we did not see noticeable effect of the inhibitors on CLL cell survival under these conditions (Fig. S4) . These results indicate that PI3Kγ also contributes to chemokine-dependent and integrin-dependent adhesion of CLL cells to stromal cells. 
Discussion
The PI 3-kinases α, β, γ, and δ collectively regulate major signaling pathways promoting CLL cell chemotaxis, cytoskeletal rearrangement, and CLL cell interaction with the microenvironment. A recent addition to CLL therapy is the PI3Kδ-specific inhibitor idelalisib that has shown significant activity in this disease [44] . Idelalisib deprives CLL cells of essential survival and proliferative stimuli received from the resident cells of the microenvironment, thus reducing lymphadenopathy and causing egress of CLL cells into peripheral blood. Upon egress, CLL cells may be more vulnerable to the conventional therapeutics used in CLL treatment. We and others have shown that idelalisib can significantly reduce malignant B cell migration in response to chemotactic stimuli [39, 45] . Idelalisib was found to affect CLL cell adhesion [32, 46] and may also affect tissueresident cells capacity for cell-cell interaction and secretion of soluble factors [39] .
Unlike protein kinases, all four class I PI3Ks phosphorylate the same target molecules and generate identical D3 phosphoinositide products, thus they are expected to exhibit some functional redundancy. Some level of redundancy may be important to ensure robust activation and finetuning of this pathway. One way in which PI3Ks may exhibit unique functions is via differential expression among cell types. PI3Kδ and PI3Kγ subunits are expressed most abundantly in hematologic cells. It was estimated that PI3Kδ contributes approximately 50% of the total PI3K activity in lymphocytes [47] , thus targeting PI3Kδ has a significant impact on lymphocyte functions that are highly dependent on D3 phosphoinositides [48] . In contrast, the contributions of PI3Kγ have only been clearly defined in T cells and myeloid cells [29, 30, 49] . PI3Kγ-deficient mice have defective antibody responses upon immunization [30] , but this may reflect impaired T cell and myeloid cell function. Moreover, PI3Kγ-deficient mouse B cells exhibited normal migration to chemokines in transwell assays and did not show altered homing to tissues when transferred to normal hosts [29] , leading to the conclusion that PI3Kγ has a minimal role in B cell migration in mice.
To delineate the respective influence of PI3Kδ and PI3Kγ in the context of human B cell malignancy, we compared idelalisib to a highly selective PI3Kγ inhibitor CZC24832 [33] . Both inhibitors were able to significantly reduce CLL migration and adhesion. As these compounds may have differing specificity, potency, and stability, we used several Fig. 8 Inhibition of either PI3Kγ or PI3Kδ significantly decreases the adhesion of CLL cells to stromal cells without affecting CLL cell survival. CLL cells were incubated for 24 h with established monolayers of human stromal cell line HS-5 in the presence of the indicated inhibitors. The adhered and non-adhered CLL cell fractions were counted by flow cytometry, gating on the live cell population expressing CD19, to determine the percent adhesion. a Impact of PI3Kγ or PI3Kγ/PI3Kδ dual inhibitors on stromal cell binding. The graph displays percent adhesion of individual CLL patient samples under different inhibitor treatment conditions. Inhibition of PI3Kγ or PI3Kδ significantly decreased the adhesion of CLL cells regardless of b ZAP70 status or c IgVH mutation status approaches to confirm selective effects under the conditions of our experiments. A pan-PI3K inhibitor GDC-0980 was found to have stronger effects on both migration and phosphorylation of Akt and its downstream targets than either PI3Kγ, PI3Kδ, or dual PI3Kδ/γ inhibitors. This is consistent with a contribution from PI3Kα/β isoforms which is not effectively blocked by PI3Kδ/γ inhibitors under the conditions of our experiments. We have also observed that pan-PI3K inhibitor but not PI3Kγ inhibitor can block Akt phosphorylation in stromal cells that do not express PI3Kγ, further confirming specificity (data not shown). Importantly, we also confirm the key conclusion of the paper regarding PI3Kγ and CLL migration using the completely independent approach of genetic silencing by CRISPRi.
PI3Kγ inhibition had a particularly strong effect on directional migration within collagen gels containing an SDF1α gradient. This suggests an important role of PI3Kγ in chemokine sensing and cell polarization toward the chemokine gradient, consistent with findings in neutrophils [23, 50, 51] . We also found that PI3Kγ inhibition had a stronger impact on cell morphology than PI3Kδ inhibition, and led to a reduction in polarization and an increase in abnormal multipolar morphologies upon exposure to a chemokine. We hypothesize that the direct linkage between PI3Kγ and chemokine receptors, via direct p101-Gβγ interactions, provides a unique and indispensable contribution to efficient chemotaxis, perhaps by controlling spatial gradients of phosphoinositides within the plasma membrane. Together, these results provide the first demonstration that PI3Kγ has unique non-redundant functions in chemokine-mediated responses in human B cell malignancies.
PI3Kγ has two unique adapter subunits p84 and p101, distinct from the p85 adapter used by PI3Kδ [52] . Whereas p84 specifically couples PI3Kγ to signaling pathways controlling oxidative burst in neutrophils [23, 50] , p101 can directly couple PI3Kγ to Gβ/γ subunits generated by ligandactivated chemokine receptors [53, 54] . We found that CLL cells express p101 but not p84 (data not shown). Both p101 and p110γ catalytic subunits showed increased expression upon activation by CD40L/IL-4 in most CLL patient samples. Consistent with these in vitro data, examination of p101 and p110γ expression in a well-annotated microarray data set [40] showed that CLL cells isolated from lymph node express higher levels of PI3Kγ subunits than CLL cells isolated from blood of the same patients. Moreover, overexpression of p101 and p110γ together significantly enhanced CLL cell migration, suggesting that CLL cell expression of functional PI3Kγ can be modulated by microenvironmental signals and can functionally impact chemokine receptor-mediated responses.
Studies in mouse and human have revealed multiple roles of PI3Kγ in immune functions. Animals genetically deficient in PI3Kγ do not show obvious defects in B cell functions; however, these mice may have developed compensatory mechanisms such as increased expression of other PI3K isoforms that obscure changes in B cell functions. Moreover, B1 and marginal zone B cells, considered as possible normal counterparts of CLL cells, were not examined in PI3Kγ-deficient mice. It remains possible that human B cells are more dependent on PI3Kγ than mouse B cells, or that our findings here may reflect unique properties of B cell malignancies. It is established that PI3Kγ plays essential roles in normal T, NK, and myeloid cell functions in mice [55] . As a result, PI3Kγ inhibition or dual PI3Kδ and PI3Kγ inhibition had anti-inflammatory activities in several diesease models in mice, attributed to inhibition of cell migration into inflammed tissues [55, 56] . Since one of the major hurdles in clinical use of idelalisib is T cellmediated toxicities [57, 58] , its tempting to speculate that dual inhibition of PI3Kδ and PI3Kγ may partly mitigate these toxicities by impairing T cell migration into sites of inflammation such as colon, lung, or liver.
Dual inhibition of PI3Kδ and PI3Kγ has been proposed to have potential benefit for CLL treatment and is currently in clinical trials [39, 59, 60] . However, a direct comparison of the relative effectiveness of dual vs. single inhibition has not been reported. We find that dual inhibition has a stronger effect on PI3K/Akt pathway activity, chemokinedependent migration and adhesion than either PI3Kδ or PI3Kγ inhibitors. While our findings do not exclude the contribution of other PI3K isoforms, they do provide the first demonstration of a distinct biological function of PI3Kγ in B cells. Additional blockade of PI3Kγ may thus improve clinical benefits via increased anti-leukemic activity and reduced T cell-mediated toxicities. interpreted data. AJM designed research, analyzed and interpreted data, supervised trainees, and wrote the manuscript.
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